Abcellera Biologics Inc ABCL

$12.27 -0.81 (-6.19%)

Valuation

Market cap
4,010,472,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,876,500
Avg volume
4,760,140
Day's range
$11.75 – $12.91
Shares out
306,611,000
Stochastic %K
43%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

OnlyFibs Oct 31, 5:26 PM
RECAP 10/30 +Pos Comments: $NUE + Freedom Capital $PCAR + Freedom Capital $ABCL + Jefferies $GTX + Freedom Broker $MDLZ + Freedom Broker
0 replies
Stocktradesmoon Oct 31, 4:37 PM
$ABCL Vertex pays $ABCL 28 million dollars upfront to use its T cell engager platform against autoimmune disease, funding all research and development itself. AbCellera keeps milestones and royalties without carrying the trial cost.
0 replies
Merlintrader Oct 31, 9:45 AM
$ABCL closed the week at $12.27 (+3.8% w/w, -6.2% Friday), below the 50-day SMA ($12.29) and above the 200-day ($6.85). RSI14 48.9. Support $11.08, resistance $14.53 (20-day range, middle). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/abcellera-biologics-stock-hub/
0 replies
OpenOutcrier Oct 30, 8:01 PM
RECAP 10/30 +Pos Comments: $NUE + Freedom Capital $PCAR + Freedom Capital $ABCL + Jefferies $GTX + Freedom Broker $MDLZ + Freedom Broker Live Breaking trading news www.openoutcrier.com
0 replies
Stocktradesmoon Oct 30, 7:52 PM
$ABCL $MRNA $LLY $REGN $SLS 👀🔥🚨ABcellera 🔥 🔥!!! -Jefferies initiates AbCellera coverage with a Buy rating -The firm highlighted the company’s antibody discovery platform and its clinical pipeline, led by ABCL635, a monthly subcutaneous NK3R antibody for vasomotor symptoms. -Sets $21 target
0 replies
ITF Oct 30, 7:48 PM
$ABCL monday is dem' scarce and the market will drop, tuesday capitulation and 5min before the bell everyone will buy, that's the senario i'm watching
0 replies
XxZeeMoneyxX Oct 30, 7:46 PM
$ABCL still on sale!! I scooped 1000 more on the day. Had too!
0 replies
Stocktradesmoon Oct 30, 7:46 PM
$ABCL $MRNA $SLS $REGN $LLY 👀🔥🚨 ABcellera 🔥 🔥!!! News OUT Today UPGRADED to $21!!!
0 replies